Wire · opportunities
WCG CenterWatch 2025 Report Shows AI Adoption Remains Uneven Across Clinical Research
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
WCG CenterWatch's 2025 benchmarking survey of 400+ sponsors, CROs, and sites reveals only 11% have fully implemented AI in clinical trials, with two-thirds still exploratory. The FDA's January 2025 draft guidance on AI in regulatory decision-making has raised stakes for organizations treating AI adoption as a pilot rather than validated process.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
If you build clinical trial software for sites or mid-market CROs, two-thirds of your market has not yet deployed AI — but large CROs like Parexel have already moved to validated systems. The FDA's AI guidance in January 2025 means AI is now a compliance requirement, not optional; organisations still piloting will need to move to production within months or lose contract tenders.
◆ Related on Wire
◆ Topics